MTVA
MetaViaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
MTVA vs peer average
61/100
MTVA vs. peer average (D vs. F)
Grade spread
D 3 · F 7
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
RNAZ is the first available peer comparator.
Loose micro-cap clinical biotech peer useful mainly for financing sensitivity and binary data-readout volatility comparison, not for mechanism-level obesity benchmarking.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
MTVA
MetaVia
RNAZ
TransCode Therapeutics
Grade
D
F
Momentum
69
8
Value
58
58
Sentiment
22
-
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs RNAZ
MTVA / RNAZ
Grade Position
In line
MTVA vs. peer average (D vs. F)
61/100
Momentum
69
MTVAValue
58
RNAZSentiment
22
-Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs MTVA
RNAZ is the first peer returned for this comparison set.